Triangle Biostatistics   Report issue

For profit Phase 2
Founded: Raleigh NC United States (2010)
Status: Acquired by Catalyst Clinical Research LLC (2019)

Organization Overview

First Clinical Trial
2017
NCT03394924
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Triangle Biostatistics

Active Ingredients

Drugs in Phase 2 Trials (1)

edp-305 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangitis (Phase 2)

Fatty Liver (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1